Lambert-Eaton myasthenic syndrome


Also found in: Dictionary, Thesaurus, Acronyms, Wikipedia.
Related to Lambert-Eaton myasthenic syndrome: myasthenia gravis

Lam·bert-Ea·ton myasthenic syn·drome (LEMS),

(lam'bert ē'tŏn),
a generalized disorder of neuromuscular transmission caused by a defect in the release of acetylcholine quanta from the presynaptic nerve terminals; often associated with small cell carcinoma of the lung, particularly in elderly men with a long history of cigarette smoking. In contrast to myasthenia gravis, weakness tends to affect solely axial muscles, girdle muscles, and less often the limb muscles; autonomic disturbances, for example, dry mouth and impotence, are common; the deep tendon reflexes are unelicitable; on motor conduction studies, responses on initial stimulation are quite low in amplitude, but they show marked posttetanic facilitation after a few seconds of exercise. Lambert-Eaton syndrome is due to loss of voltage-sensitive calcium channels located on the presynaptic motor nerve terminal. See: myasthenic syndrome.

Lambert-Eaton myasthenic syndrome

(lăm′bərt-ēt′n)
n.
An autoimmune disorder that affects neuromuscular transmission and is usually associated with lung cancer, characterized by weakness of muscles especially in the limbs.

Lambert-Eaton myasthenic syndrome

(lam'bert-et'on)
[Edward Howard Lambert, U.S. physiologist, 1915–2003; Lee McKendree Eaton, U.S. physician, 1905–1958]
An autoimmune syndrome in which weakness of the proximal muscles (e.g., around the shoulder and the hip girdle), diminished reflexes, and autonomic dysfunction are found. The syndrome is often associated with small cell carcinoma of the lung or other malignancies. Its cause is a unique antibody against presynaptic calcium channels.
Synonym: Eaton-Lambert syndrome
References in periodicals archive ?
Lambert-eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy.
In addition, the company stated that it had held a productive pre-NDA meeting with the FDA regarding Firdapse for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) and, based on the discussions at that meeting, its believes its Phase 3 clinical programme will provide acceptable support for submission of an NDA for Firdapse for LEMS.
Catalyst Pharmaceuticals' Firdapse 10 mg tablets for the treatment of adults with Lambert-Eaton Myasthenic Syndrome, or LEMS, has been approved by the FDA.
Net proceeds from the proposed offering will be utilised by the company for the continuing development of Firdapse for the treatment of Lambert-Eaton Myasthenic Syndrome, pre-commercialisation activities relating to Firdapse, continuing development of CPP-115 as well as for general corporate purposes.
Lambert-Eaton Myasthenic Syndrome, or LEMS, is a rare autoimmune disorder characterised by muscle weakness of the limbs.
"We are extremely focused on executing on our launch-readiness plan as we prepare for the potential commercial launch of Firdapse for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) early next year," said Patrick McEnany, chairman and CEO of Catalyst Pharmaceuticals.
M2 EQUITYBITES-April 2, 2014-Catalyst Pharmaceutical Partners concludes patient enrollment in pivotal Phase 3 trial of Firdapse in Lambert-Eaton Myasthenic Syndrome patients
Food and Drug Administration for Firdapse for the symptomatic treatment of Lambert-Eaton myasthenic syndrome. Last month, Catalyst announced the results of its recent positive Type C meeting with the FDA and reported that the minutes of the meeting received from the Agency reflect the FDA's advice to Catalyst that its proposed filing package would be sufficient for submission of an NDA for Firdapse.